BeOne Medicines (ONC) Non-Current Assets (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Non-Current Assets of $2.0 billion for Q1 2026, little changed year-over-year from $1.9 billion in Q1 2025, and little changed quarter-over-quarter from $2.0 billion in Q4 2025.
BeOne Medicines (ONC) Non-Current Assets (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Non-Current Assets for 12 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets changed 0.38% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (changed 0.38% YoY), while the FY2025 annual figure was $2.0 billion, up 1.33% from the prior year.
- Non-Current Assets was little changed at $2.0 billion in Q1 2026 per ONC's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.0 billion in Q2 2025 and bottomed at $976.8 million in Q3 2022.
- Historically, Non-Current Assets has averaged $1.6 billion across 5 years, with a median of $1.8 billion in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 57.82% — and 2026, when it climbed 0.38%.
- BeOne Medicines' Non-Current Assets stood at $1.2 billion in 2022, then jumped by 36.65% to $1.6 billion in 2023, then climbed by 20.44% to $1.9 billion in 2024, then rose by 1.33% to $2.0 billion in 2025, then declined by 0.14% to $2.0 billion in 2026.
- Business Quant data shows ONC's Non-Current Assets at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Bn |
| Mar 31, 2026 | 1.95 Bn |
| Dec 31, 2025 | 1.95 Bn |
| Sep 30, 2025 | 1.97 Bn |
| Jun 30, 2025 | 1.99 Bn |
| Mar 31, 2025 | 1.95 Bn |
| Dec 31, 2024 | 1.93 Bn |
| Sep 30, 2024 | 1.92 Bn |
| Jun 30, 2024 | 1.87 Bn |
| Mar 31, 2024 | 1.76 Bn |
| Dec 31, 2023 | 1.60 Bn |
| Sep 30, 2023 | 1.47 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.17 Bn |
| Sep 30, 2022 | 976.85 Mn |
| Jun 30, 2022 | 1.03 Bn |
| Mar 31, 2022 | 1.07 Bn |
| Dec 31, 2021 | 921.65 Mn |
| Sep 30, 2021 | 853.50 Mn |